27 results about "Elimination" patented technology

The invention discloses a highly inert Gd-DOTA-based contrast agent with a hydrophobic side chain as well as a preparation method and application of the highly inert Gd-DOTA-based contrast agent, and two novel Gd-DOTA-based contrast agents Gd-L1 and Gd-L2 are successfully developed by respectively connecting hydrophobic 3-phenyl propylamine and 3, 3-diphenyl propylamine to Gd-DOTABA. The two novel Gd-DOTA-based contrast agents remarkably improve the chemical inertness of the complex, the dissociation half-life period of the complex in a 1 M HCl solution at 37 DEG C is about 5 times that of Gd-DOTA, and a powerful guarantee is provided for clinical safety; the MRI (Magnetic Resonance Imaging) performance of the liver in a mouse shows that Gd-L1 is equivalent to commercially available Gd-BOPTA and is suitable for imaging of a liver and gall system; after the Gd-L2 is combined with the human serum albumin, the longitudinal relaxation rate is obviously increased (r1 = 14.8 mM <-1 > s <-1 >, 1.4 T, 37 DEG C), the blood elimination half-life period in a rabbit model is about 18 minutes, and the Gd-L2 is suitable for vascular MRI (Magnetic Resonance Imaging). The two contrast agents avoid the spleen residual problem, the organ accumulation possibility is reduced, and a safer and more efficient MRI diagnostic tool is provided for clinic.

A system and method for rendering a diseased organ implant eligible, the method including acquiring an image data set of a potential donor organ, identifying one or more disease states in the potential donor organ, wherein the one or more disease states render the organ ineligible for transplant, harvesting the potential donor organ, applying histotripsy therapy, and confirming elimination / reduction of the disease state in the potential donor organ.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, “treatment” generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, "treatment" generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The application discloses a slow-release micro-pellet containing gamma-aminobutyric acid and a preparation method and application thereof. Gamma-aminobutyric acid is wrapped in a mucosal adhesion material in a fluidized bed to form a micro-pellet, and the micro-pellet is dispersed in an aqueous alginate solution to form a micro-pellet with a size of about 1-10 mm through calcium ion cross-linking. The slow-release micro-pellet overcomes the shortcomings of a product without cross-linked alginate, such as poor slow-release effect and easy burst release of active ingredients, has a biological membrane adhesion property, can realize stable release of GABA in a small intestine for at least 8 hours, presents obvious slow-release characteristics in a beagle dog in vivo, significantly delays a peak time, significantly reduces a peak concentration, significantly prolongs an elimination half-life, keeps a blood drug concentration stable and small fluctuation, and significantly improves a relative oral bioavailability. The application has the advantages of a soft and elastic texture after water absorption, chewability, and flexible and various taking modes. In addition, the application has a simple preparation process and can realize industrial production.

This invention belongs to the field of bioengineering technology and discloses a method for specific targeting and scarless simultaneous elimination blue KPC‑2 Gene and IncL plasmid sgRNA sequences, CRISPR / Cas9 vector system and applications. This system targets the sgRNA of the IncL plasmid. blue KPC‑2 The IncL-type plasmid of the gene was designed with an sgRNA that specifically recognizes the conserved sequence at its origin of replication, thus eliminating the drug resistance gene while disrupting the plasmid's replication ability. Conjugation transfer to recipient bacteria significantly improved vector delivery efficiency. An arabinose-inducible promoter was used to control Cas9 gene expression, improving system stability and editing success rate. The vector carries a sucrose-inducible self-eliminating gene, enabling controlled vector self-elimination. This system is not a simple superposition but rather constitutes a time-controlled operational flow: efficient delivery via conjugation, controlled cleavage via induction, and finally, induced self-elimination.

The application discloses an ether bond connected linker-drug molecule and an antibody conjugated drug, a preparation method and application thereof, and particularly discloses a compound represented by formula (1) or (2), or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture form thereof, or a pharmaceutically acceptable salt, a prodrug or a solvate thereof, a composition containing the same or a use thereof. The compound of the application is connected with a drug molecule through an ether bond through a polypeptide (VC, VA, AAA)-PAB (self-elimination group) on a linker, greatly enhances the drugability (including hydrophilicity and stability) of the compound to an antibody drug conjugate, reduces the drug clearance in the body, and improves the tumor treatment effect.

The application belongs to the field of biomedical engineering, and discloses a human live mucosa organoid and a construction method and application thereof. The construction of the organoid comprises the following steps: preparing a cell gel compound, filling the cell gel compound into a support, implanting the support into a nude mouse subcutaneously after gelation, and obtaining the human live mucosa organoid after culturing for 1-3 weeks. The application also discloses the application of the organoid in disease research or drug screening. The application constructs a sustainable in-vivo biomimetic air-mucosa gas-liquid interface, realizes the transition of mucosa from an "ex-vivo static model" to an "in-vivo dynamic live system", and realizes the comprehensive evaluation of the curative effect of anti-infection drugs from three dimensions of pathogenic bacteria elimination, inflammation reaction regulation and immune cell recruitment inhibition in application, thereby breaking through the limitation of traditional models that can only evaluate the in-vitro bacteriostatic activity and being more consistent with the actual effect of clinical drug treatment.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, “treatment” generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The invention belongs to the technical field of toxicological evaluation, and discloses a photoresponsive liver chip system for evaluating drug immunotoxicity, which comprises a liver chip with a multilayer structure, a photoresponsive immune cell elimination reagent and an illumination device. The invention also discloses an application of the photoresponsive liver chip system in drug immunotoxicity evaluation, which comprises the following steps: firstly, in a state that the photoresponsive immune cell elimination reagent is not activated, performing a first round of toxicity detection on a to-be-detected drug to obtain baseline toxicity data; then, activating a reagent through illumination, and specifically eliminating immune cells in the chip; then carrying out a second round of toxicity detection; the immunotoxicity contribution of the to-be-detected medicine is accurately evaluated by comparing the difference of two rounds of toxicity detection data. The method realizes sequential resolution evaluation on the direct toxicity and the immune-mediated toxicity of the drug on the same biological sample, overcomes the defects that a traditional method is tedious in operation and cannot distinguish toxicity sources, and has the advantages of rapidness, accuracy and high throughput.

The application discloses an intestinal microbial marker combination for cirrhosis diagnosis and application thereof, which is composed of 8 specific intestinal bacterial species. The application accurately identifies the core combination from 181 differential characteristics by performing metagenomic sequencing on fecal samples of cirrhosis patients and healthy controls, and combining random forest, LASSO regression and recursive feature elimination algorithms. The random forest diagnosis model based on the 8 markers realizes an excellent performance of area under curve (AUC) 0.841, sensitivity 84.3% and specificity 83.7% on a completely independent test set, and the performance does not decrease compared with the full feature model in the case of reducing the number of characteristics by 86.9%. The marker combination provided by the application is highly simplified and has strong discrimination, and provides a clear and efficient microbiological basis and technical scheme for developing a cirrhosis non-invasive diagnosis kit, a gene chip and other products based on intestinal flora.

Traditional CYP2E1 activity detection adopts an elimination phase 6-hydroxy chlorzoxazone and chlorzoxazone ratio, but is interfered by UGT enzyme elimination, so that activity evaluation is distorted, and the CYP2E1 metabolism generation capability cannot be truly reflected. The invention discloses a simple method, system and kit for characterizing CYP2E1 activity. The method comprises the following steps: a, obtaining a biological sample after chlorzoxazone is administered; b, determining the concentration ratio of 6-hydroxy chlorzoxazone to chlorzoxazone of the sample at the highest time point of the absorption phase; the highest time point of the absorption phase is the peak reaching time of the concentration of 6-hydroxychlorzoxazone. It is found that after chlorzoxazone is applied to an organism, blood should be taken from the absorption phase of chlorzoxazone, and the activity of CYP2E1 can be really reflected.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, "treatment" generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The present invention includes a method of detecting and treating a patient suspected of having Barrett's esophagus comprising: obtaining a biological sample from an esophagus of the patient; determining a microbiome in the biological sample by detecting the presence of bacteria by plasmid dilution verification or quantitative polymerase chain reaction (qPCR); wherein if the patient has a microbiome indicative of an increased risk of esophageal cancer threating the patient with at least one of: removing at least part of the esophagus, esophagectomy probiotic therapy, or chemically targeting elimination of bacteria indicative of an increased risk of esophageal cancer.

The application provides a hydroxyl-substituted beraprost derivative, a synthesis method and application thereof, and belongs to the technical field of drugs.The compound is a coupling compound containing beraprost and a nitric oxide donor.The compound solves the defects of short elimination half-life of beraprost sodium, multiple single-day administration, saturation ceiling effect of curative effect, short metabolic half-life of NO which is a gas and is rapidly decomposed in a solution, and the like, the new compound reduces the original beraprost administration dose and administration frequency, and simultaneously utilizes the relaxation of smooth muscle caused by the release of NO molecules in the body of the compound, so that the two drugs play a synergistic effect through double action, and the effectiveness and safety of the drug are improved.

Treatment compositions and methods for treating and / or preventing actinic keratosis comprising applying a chlorin treatment composition in a topical form to one or more actinic keratosis lesions. A treatment composition preferably comprises a copper chlorin, such as a sodium copper chlorophyllin complex, trisodium copper chlorin p6, disodium copper isochlorin e4, or trisodium copper chlorin e6. A treatment composition comprises around 0.002% to around 0.1% by weight of copper chlorin. Treatments disclosed herein may result in elimination of the actinic keratosis lesions.

The invention discloses a paclitaxel derivative. The paclitaxel derivative is a compound as shown in a molecular formula 6. The invention also claims to protect a preparation method and application of the paclitaxel derivative, and an antitumor drug containing the paclitaxel derivative. The paclitaxel derivative provided by the invention can reduce the distribution of drugs to non-target tissues and organs, accelerate the in-vivo elimination process of the drugs, reduce the residence time of the drugs in blood, and reduce toxic and side effects such as blood toxicity and neurotoxicity of the drugs.

The objective is to obtain a biological elimination device that can prevent the target organism from becoming accustomed to a specific elimination method, depending on the number of times the target organism has invaded. [Solution] The system includes: an acquisition unit 7 that acquires detection information indicating that an organism to be eliminated 3 has entered the monitoring area 12 from a detection unit 5 that detects when an organism to be eliminated 3 has entered the monitoring area 12; and a control unit 11a that controls the elimination execution unit 6, which performs elimination to prevent the organism to be eliminated 3 from entering an intrusion-prohibited area, to change the elimination means executed by the elimination execution unit 6 to a different elimination means than the one executed when the cumulative number of eliminations was less than the predetermined number, if the cumulative number of eliminations, which is the number of times the organism to be eliminated 3 has entered the monitoring area 12, is greater than or equal to a predetermined number, based on the detection information.

The invention provides a physiological state risk early warning in-vitro detection system and method based on multi-marker conjoint analysis, and is applied to the technical field of data processing. According to the application, serum, urine and tissue fluid are taken as samples, and concentration, activity response and molecular binding characteristics of core markers such as blood glucose and interleukin-6 are captured in a targeted manner through a multi-dimensional marker synchronous detection technology. And after abnormal value elimination and standardized calibration, a random forest joint reasoning early warning model is constructed by combining a multi-marker coordination rule and clinical standard fusion data, and physiological status risk grading identification is realized. Key information such as risk types and core driving markers is determined through verification of marker specificity rules and metabolic pathway associated data, and finally accurate risk early warning details including dimensions such as metabolic abnormalities and inflammatory reactions are generated, so that a complete technical closed loop is formed.

The application relates to the field of simulation devices and application methods of pharmacokinetics, in particular to a device for simulating an in-vivo two-compartment model and a method for accurately predicting the detoxification effect of fat emulsion, and independently designs a two-pool four-pump device, which comprises two pools for simulating a two-compartment system and four pump devices serving as a driving system for transporting liquid. The device has the characteristics of uniform stirring and constant system temperature, and adopts a dynamic environment of liquid continuous flow to simulate the distribution and elimination of drugs in the body. Based on the phenomenon that liposoluble drug molecules can be captured by fat emulsion and the capturing degree is positively correlated with the lipophilicity of the drugs, fat emulsion with adjustable flow rate is injected on the basis of the two-pool four-pump device, the change of the drug concentration is detected by using a high-performance liquid chromatograph, the dose-effect relationship between the fat emulsion infusion speed and the capturing effect of drugs with various properties is established, and the accuracy of the dose-effect relationship in in-vivo prediction is verified through animal experiments.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, "treatment" generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

In accordance with at least one aspect of this disclosure, a method for improving clearance and elimination of tumor targeted anti-cancer drugs from a patient, comprises, administering to a patient an anti-cancer drug that is eliminated into urine, and administering to the patient one or more supplemental therapies at a predetermined time after administering the anti-cancer drug. The predetermined time can be determined as a function of at least one of: the anti-cancer drug, the supplemental therapy, a tumor type, and / or a current physiological condition of the patient.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, "treatment" generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The invention discloses a system for common hepatic artery nerve mapping and liver function regulation, and relates to the technical field of nerve mapping and regulation systems. Comprises: an interventional catheter unit configured to be delivered to a target segment of an abdominal trunk or a common hepatic artery via a blood vessel; the electrical stimulation and mapping unit is electrically connected with the interventional catheter unit and is configured to apply a controllable electrical stimulation signal to the target section and collect an impedance signal of a stimulation part so as to evaluate a catheter attaching state; and the physiological signal monitoring unit is configured to monitor at least one physiological parameter related to the sympathetic nerve activity or the liver metabolism function in real time in the electrical stimulation process. According to the invention, a neurological function mapping mechanism guided by electrical stimulation is introduced; electrical stimulation is applied to different artery segments, and changes of key physiological indexes such as blood pressure and blood sugar are monitored in real time, so that the system can accurately recognize neural enrichment with the strongest response to stimulation; the defect that blind elimination is carried out only depending on anatomical experience in the prior art is overcome.

A system and method for rendering a diseased organ implant eligible, the method including acquiring an image data set of a potential donor organ, identifying one or more disease states in the potential donor organ, wherein the one or more disease states render the organ ineligible for transplant, harvesting the potential donor organ, applying histotripsy therapy, and confirming elimination / reduction of the disease state in the potential donor organ.

The invention discloses a preparation method of a polypyrrole nano-drug loaded with gambogic acid and heme and modified by hyaluronic acid. The preparation method comprises three main steps of synthesis of HNPs (at) PPy, synthesis of HG (at) PPy NPs and synthesis of HG (at) PPy-HA NPs. The polypyrrole nano-drug loaded with gambogic acid and heme and modified by hyaluronic acid, which is prepared by the method disclosed by the invention, is in a black spherical shape, is uniformly dispersed, has good penetrability and obvious controlled release effect, has a long-circulation effect in vivo, does not have obvious cytotoxicity and animal toxicity, is good in biocompatibility, and can be used for preparing a nano-drug. An obvious killing effect on tumor cells is achieved, and the effect is more obvious after photothermal therapy is combined; the method is verified in anti-lung cancer effect research, and significant exploration is carried out on establishment of a lung cancer chemotherapy phototherapy system. In addition, polypyrrole has good biocompatibility, so that the water solubility, stability and elimination half-life period of gambogic acid are improved, and the toxic and side effects of gambogic acid are reduced.